Colchicine to reduce inflammation after a first blood clot in the leg
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if colchicine, a medicine used for gout, can reduce inflammation after a first deep vein thrombosis (blood clot in a large leg vein). It might help prevent long-term leg problems from the clot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have had your first blood clot in a large leg vein (like the popliteal or higher) confirmed by a scan.
- You cannot be allergic or sensitive to colchicine.
- You cannot have active diarrhea, inflammatory bowel disease, or certain blood disorders.
- You cannot have a recent or active infection, severe liver disease, or known active cancer.
- You cannot be taking certain medications like strong antibiotics (e.g., erythromycin) or immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving medicine to prevent blood clots during varicose vein treatment is safe and helpful. It focuses on people having a minimally invasive procedure on enlarged leg veins under local anesthesia.
This study tests whether adding the drug colchicine to standard blood-thinner treatment can help people with a first blood clot in their leg. Colchicine is an anti-inflammatory medicine that may reduce the risk of another clot and related complications.
This study tests whether a medication called colchicine can help prevent amputation in people with severe leg blood flow problems who just had surgery or a catheter procedure to restore blood flow. Colchicine is an anti-inflammatory drug that may help protect the leg tissue after treatment.
This trial tests whether taking colchicine (a medicine used for gout and inflammation) after a recent mild or moderate stroke can help prevent another stroke. If it works, it could offer a new way to reduce stroke risk.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
This study tests whether a low dose of the medicine colchicine can help prevent blood clots after a TAVR procedure, which replaces a narrowed heart valve. If you've recently had TAVR, taking colchicine might lower your risk of clots.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.